17783-46-9

Usage

Uses

Used in Pharmaceutical Industry:
Bemitil is used as a therapeutic agent for neurological disorders and mental fatigue due to its neuroprotective, anti-fatigue, and anti-stress properties.
Used in Cognitive Function Enhancement:
Bemitil is used as a cognitive enhancer to improve memory and cognitive function, making it a promising compound for the development of therapeutic agents for neurological and mental health conditions.
Used in Physical Performance Improvement:
Bemitil is used as a performance enhancer to improve physical performance, enhance endurance, and increase tolerance to stress.

Upstream product

• 100-46-9 benzylamine 
• 52321-02-5 diethyl cis-1-methylpyrrolidine-2,5-dicarboxylate 
• 869-10-3 diethyl 2,5-dibromoadipate 

Downstream Products

• 67571-90-8 3-benzyl-3,8-diazabicyclo[3.2.1]octane 
• 96483-83-9 3-benzyl-3,8-diazabicyclo[3.2.1]octane-2,4-dione 
• 51102-42-2 8-methyl-3,8-diazabicyclo[3,2,1]octane 
• 17783-48-1 3-benzyl-8-methyl-3,8-diazabicyclo[3.2.1]octane 

Relevant academic research and scientific papers

NOVEL 3,8-DIAZA-BICYCLO[3.2.1]OCTANE- AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-CARBOXYLIC ACID ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS

This invention relates to novel 3,8-diaza-bicyclo[3.2.1]octane-and 3,9-diaza- bicyclo[3.3.1]nonane-3-carboxylic acid ester derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these co

NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS

This invention relates to novel substituted diazabicyclo derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions

NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE

This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compound

NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE

This invention relates to novel diazabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compoun

Diazabicyclooctanes and diazabicycloheptanes

Twelve analogs of diethylcarbamazine as prepared by acylation of 3- and 8-methyl-3,8-diazabicyclo[3.2.1]octane, 2-methyl-2,5-diazabicyclo[2.2.2]octane, and 2-methyl-2,5-diazabicyclo [2.2.1]heptane with diethylcarbamyl chloride, ethyl chloroformate, ethyl isocyanate, and cyclohexanecarbonyl chloride. These compounds are formally derived from diethylcarbamazine in possessing two- or one-carbon bridges over the piperazine ring. The compounds have utility as antifilarial agents and as bronchodilators.

Antifilarial agents. Diazabicyclooctanes and diazabicycloheptanes as bridged analogs of diethylcarbamazine

Twelve analogs of diethylcarbamazine (DEC) were prepared by acylation of 3 and 8 methyl 3,8 diazabicyclo[3.2.1]octane, 2 methyl 2,5 diazabicyclo[2.2.2]octane, and 2 methyl 2,5 diazabicyclo[2.2.1]heptane with diethylcarbamyl chloride, ethyl chloroformate, ethyl isocyanate, and cyclohexanecarbonyl chloride. These compounds are formally derived from DEC in possessing two or one carbon bridges over the piperazine ring. When evaluated against Litomosoides carinii in the gerbil, all compounds strongly suppressed blood microfilaremia levels but did not affect the adult worms. Several compounds were nearly equivalent to DEC in activity. The results are discussed in terms of molecular model studies and receptor site theory.